On August 17, Argenx SE rose 5% in pre-market trading, trading at $918.18/share, with turnover of $49,500.

The move was driven by the company announcing that its drug Vyvgart Hytrulo (efgartigimod) met the primary endpoint in a Phase 3 clinical trial evaluating its efficacy in adults with autoimmune myositis. Patients treated with the drug showed a statistically significant improvement in mean total improvement score at week 52 compared with placebo, with a 15.4-point advantage. Treatment benefits emerged as early as week 4 and were sustained through the 52-week treatment period, including during steroid tapering. Notably, the trial also demonstrated significant improvement in immune-mediated necrotizing myopathy (IMNM), a disease subtype with no currently approved therapies, marking the first Phase 3 trial to show meaningful efficacy in this indication. The data reinforces the expanding clinical utility of Argenx's FcRn platform beyond its approved indications in generalized myasthenia gravis and CIDP.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)